Pfizer Inc.

AI Score

0

Unlock

26.41
-0.39 (-1.46%)
At close: Jan 14, 2025, 3:59 PM
26.41
0.02%
Pre-market Jan 15, 2025, 04:04 AM EST
undefined%
Bid 26.39
Market Cap 149.64B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 0.75
PE Ratio (ttm) 35.21
Forward PE n/a
Analyst Hold
Ask 26.41
Volume 21,869,050
Avg. Volume (20D) 43,218,409
Open 26.81
Previous Close 26.80
Day's Range 26.27 - 26.87
52-Week Range 24.48 - 31.54
Beta undefined

About PFE

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable an...

Sector Healthcare
IPO Date Jun 1, 1972
Employees 88,000
Stock Exchange NYSE
Ticker Symbol PFE

Analyst Forecast

According to 13 analyst ratings, the average rating for PFE stock is "Hold." The 12-month stock price forecast is $32, which is an increase of 21.19% from the latest price.

Buy 38.46%
Hold 53.85%
Sell 7.69%
Stock Forecasts

Next Earnings Release

Pfizer Inc. is scheduled to release its earnings on Feb 4, 2025, before market opens.
Analysts project revenue of $17.13B, reflecting a 20.22% YoY growth and earnings per share of 0.46, making a 360.00% increase YoY.
4 weeks ago · Source
+4.67%
Pfizer shares are trading higher after the company... Unlock content with Pro Subscription
2 months ago · Source
-4.69%
Shares of vaccine stocks are trading lower After President-elect Trump nominated Robert F. Kennedy Jr. to lead the HHS.